Beyond The Numbers: 6 Analysts Discuss Kimberly-Clark Stock
Portfolio Pulse from Benzinga Insights
Kimberly-Clark (NYSE:KMB) has received mixed analyst ratings over the past three months, with a recent shift towards a more bullish outlook. The average 12-month price target is now $125.00, a slight decrease from the previous $127.50. Analyst actions include maintaining, raising, and lowering ratings and price targets, reflecting varied perceptions of the company's market position. Kimberly-Clark, known for its personal care and consumer tissue products, shows a positive revenue trend but lags in revenue growth compared to industry peers. Its financials indicate strong profitability and effective cost management, though it faces challenges in efficiently using equity capital.

March 01, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Kimberly-Clark has seen a mix of analyst ratings, with a recent trend towards bullishness. The average price target has been adjusted to $125.00, indicating a slight decrease in expectations. The company's financial performance shows strong profitability but faces challenges in revenue growth and equity utilization.
The mixed analyst ratings and slight decrease in the average price target suggest a cautious but slightly optimistic outlook for Kimberly-Clark. The company's strong profitability is a positive sign, but the challenges in revenue growth and equity utilization may temper short-term stock performance expectations.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100